Literature DB >> 21632171

An overview of biomarkers for the ovarian cancer diagnosis.

Bei Zhang1, Feng Feng Cai, Xiao Yan Zhong.   

Abstract

Even though there are a lot of options in treating gynecological malignancies, ovarian cancer still remains a leading cause of death. Diagnosis at an early stage is the most important determinant of survival. Current diagnostic tools applied at clinics have had very limited success in early detection. Discovery of new diagnostic biomarkers/panels for early diagnosis of ovarian cancer is one of the main challenges of modern medicine. With the progress of techniques in genomics and proteomics, numerous molecular biomarkers/panels were identified and showed promise for ovarian cancer diagnosis, but still need further validation. This article summarizes various types of markers investigated by different strategies/technologies for the ovarian cancer diagnosis at present, including gene-, protein-based and emerging ovarian cancer indicators (such as microRNA-, metabolite-based). Before biomarker tests are translated for routine use, more researches, such as retrospective and prospective clinical trials, are needed to evaluate the overall clinical utility of the tests.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21632171     DOI: 10.1016/j.ejogrb.2011.04.023

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  34 in total

1.  Immunoassays for the cancer biomarker CA125 based on a large-birefringence nematic liquid-crystal mixture.

Authors:  Shih-Hung Sun; Mon-Juan Lee; Yun-Han Lee; Wei Lee; Xiaolong Song; Chao-Yuan Chen
Journal:  Biomed Opt Express       Date:  2014-12-23       Impact factor: 3.732

Review 2.  Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.

Authors:  Khalid El Bairi; Abdul Hafeez Kandhro; Adel Gouri; Wafaa Mahfoud; Noureddine Louanjli; Brahim Saadani; Said Afqir; Mariam Amrani
Journal:  Cell Oncol (Dordr)       Date:  2016-12-15       Impact factor: 6.730

3.  Low expression of microRNA-1908 predicts a poor prognosis for patients with ovarian cancer.

Authors:  Changcai Teng; Hong Zheng
Journal:  Oncol Lett       Date:  2017-08-03       Impact factor: 2.967

4.  Expression of claudin-5, -7, -8 and -9 in cervical carcinoma tissues and adjacent non-neoplastic tissues.

Authors:  Jianyou Zhu; Rugang Wang; Hongyun Cao; Haipeng Zhang; Shaoyan Xu; Aiyun Wang; Bin Liu; Yongtao Wang; Ruicai Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 5.  Proteomics of ovarian cancer: functional insights and clinical applications.

Authors:  Mohamed A Elzek; Karin D Rodland
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

6.  Overexpression of Rab27B is correlated with distant metastasis and poor prognosis in ovarian cancer.

Authors:  Ping Ren; Xiao-Qing Yang; Xiao-Lu Zhai; Yu-Quan Zhang; Jian-Fei Huang
Journal:  Oncol Lett       Date:  2016-06-29       Impact factor: 2.967

7.  Ascites analysis by a microfluidic chip allows tumor-cell profiling.

Authors:  Vanessa M Peterson; Cesar M Castro; Jaehoon Chung; Nathan C Miller; Adeeti V Ullal; Maria D Castano; Richard T Penson; Hakho Lee; Michael J Birrer; Ralph Weissleder
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

8.  Dual detection of cancer biomarker CA125 using absorbance and electrochemical methods.

Authors:  Israa Al-Ogaidi; Zoraida P Aguilar; Savan Suri; Honglei Gou; Nianqiang Wu
Journal:  Analyst       Date:  2013-10-07       Impact factor: 4.616

Review 9.  In 2014, can we do better than CA125 in the early detection of ovarian cancer?

Authors:  Joshua G Cohen; Matthew White; Ana Cruz; Robin Farias-Eisner
Journal:  World J Biol Chem       Date:  2014-08-26

10.  New biomarkers in peripheral blood of patients with ovarian cancer: high expression levels of miR-16-5p, miR-17-5p, and miR-638.

Authors:  Mukaddes Avsar Saral; Seref Bugra Tuncer; Demet Akdeniz Odemis; Ozge Sukruoglu Erdogan; Seda Kilic Erciyas; Pınar Saip; Sevda Ozel; Hulya Yazici
Journal:  Arch Gynecol Obstet       Date:  2021-08-09       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.